Jiayao Zhang, Chenming Liu, Fangzheng Zhou, Baochun Lu
{"title":"Sporadic pancreatic desmoid-type fibromatosis with curative resection: A case report.","authors":"Jiayao Zhang, Chenming Liu, Fangzheng Zhou, Baochun Lu","doi":"10.1097/MD.0000000000041924","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Desmoid-type fibromatosis (DF) is an uncommon, locally invasive, non-metastatic soft-tissue neoplasm with variable and unpredictable manifestations. The therapeutic arsenal of DF therapy is consistently expanding; however, there remains no standard treatment modality. Sporadic pancreatic DF is rarely described in current literature, reflecting a significant deficiency in clinical treatment experience, this case aims to share some clinical experiences that can serve as a reference for managing this rare disease.</p><p><strong>Patient concerns: </strong>A 36-year-old male presented with occasional abdominal discomfort and weight loss over a year. Ultrasound revealed a large mass in the pancreatic tail, which was not observed a year ago.</p><p><strong>Diagnoses: </strong>The diagnosis of DF was confirmed by immunohistochemistry nuclear staining of β-catenin.</p><p><strong>Interventions: </strong>Distal pancreatectomy with splenectomy was performed and the patient received no further therapy.</p><p><strong>Outcomes: </strong>After 13 months of follow-up, no recurrence or distant metastasis was observed.</p><p><strong>Lessons: </strong>DF is a distinct rare tumor entity, sporadic pancreatic DF is even rarer. It is imperative to select the individualized treatment strategy for each patient to optimize tumor control and enhance quality of life.</p>","PeriodicalId":18549,"journal":{"name":"Medicine","volume":"104 12","pages":"e41924"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936541/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MD.0000000000041924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale: Desmoid-type fibromatosis (DF) is an uncommon, locally invasive, non-metastatic soft-tissue neoplasm with variable and unpredictable manifestations. The therapeutic arsenal of DF therapy is consistently expanding; however, there remains no standard treatment modality. Sporadic pancreatic DF is rarely described in current literature, reflecting a significant deficiency in clinical treatment experience, this case aims to share some clinical experiences that can serve as a reference for managing this rare disease.
Patient concerns: A 36-year-old male presented with occasional abdominal discomfort and weight loss over a year. Ultrasound revealed a large mass in the pancreatic tail, which was not observed a year ago.
Diagnoses: The diagnosis of DF was confirmed by immunohistochemistry nuclear staining of β-catenin.
Interventions: Distal pancreatectomy with splenectomy was performed and the patient received no further therapy.
Outcomes: After 13 months of follow-up, no recurrence or distant metastasis was observed.
Lessons: DF is a distinct rare tumor entity, sporadic pancreatic DF is even rarer. It is imperative to select the individualized treatment strategy for each patient to optimize tumor control and enhance quality of life.
期刊介绍:
Medicine is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties.
As an open access title, Medicine will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine’s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.